Investment Opportunities

BioSciCon, Inc., is a small business, women’s owned, S-corporation in Rockville, Maryland. The company has been sponsoring development of a new in vitro diagnostic medical device from the idea (US patent in 2000) to commercial products (2004), and additional products to improve the marketing and sale of the parent device.

In 2005, the commercialization of BioSciCon’s products was given to a subsidiary company, the MarkPap LLC, with the authority to license MarkPap® products, to comply with regulatory requirements for receiving marketing approval in the US and internationally, and to enter into alliances and other business models with other companies in order to promote the MarkPap technology commercialization. In 2008, MarkPap LLC will be opened for accepting new members (equity sale), and will offer exclusive licenses on manufacturing, marketing, distribution and sale of these products. Licenses will be limited by scope, territory, time and milestones

Investments are handling by the local bank via separate accounts. Potential investors are invited to discuss with our financial advisors at the bank for the opportunity to invest into equity and/or into programs.

Investments into equity are handled as LLC membership percent for contribution/ distribution. They will be transformed into common shares when LLC will become C-Corp.

Investments into programs are considered as co-development and are handled as a percent of revenue or royalty.

LLC welcomes new members. The LLC recognizes founding members, corporate members, individual members active and passive, contributors and member-managers. Membership contributions are conditio sine qua non for the membership. Contributions could be monetary and non-monetary (service, property, real estate). Minimal contribution is $1.00. Membership rights are earned after a contribution of a minimum $50,000. Full voting rights guarantee only a contribution of 10% and above of the current LLC value estimated to be at 14 million dollars. Currently, we are seeking investors to enable MarkPap LLC to start selling MarkPap Test (Kits) and MarkPap Solution in 2009. Details for this Investment Offering will be provided on request.

Interested potential investor should Contact Us for further information.

Market Needs

There are two markets of consideration, US and World. The US market is mature and is well known: 100 million American women at risk, 50 million Pap tests per year, 20 million American women do not participate, 3.5 million women are Pap test positive and subject to further diagnostic procedures, approximately 2.5 million are found with benign conditions, about 600 thousand are found with HSIL (severe dysplasia) and subject to diagnostic therapy procedures for removal of lesions, about 40,000 intraepithelial cancers (CIN) are removed, 12,000 develop invasive cervical cancers and 4,000 die of this cancer. Pap test has reduced the mortality of cervical cancer for 85% (between years of 1955 and 2005). Recently, this test is combined with HPV testing and new guidelines have included HPV infection in categorization of the degree of the disease. Additional technologies have been added in order to improve the original Pap test. With all these "improvements" the Pap test became expensive and not affordable for the world.

There are 6.5 billion humans living on planet Earth, one half of them are women. At lest one half, or 1.7 billion women are at risk for cervical cancer. WHO reports that about 500,000 women develop cervical cancer annually, one half of them die. Three out of four come from the developing countries. Developed countries protect their women with Pap test (in vitro diagnostic medical device for early detection of cervical lesion that, if not removed on time and cured, could progress into cervical cancer). Developing countries cannot afford the cost of Pap test that runs between 40-100 dollars in Maryland, USA. By some estimates, the developing countries cannot afford more than $5.00 per test, the low price that cannot be offered by the current technologies on this market. Alternative methods have been ineffective.

MarkPap technology, because of the biomarker has potentials to become the contemporary replacement for conventional Papanicolaou staining and to enter the Pap test market worldwide as a technology intended for primary screening to detect early cytological signs of lesion that, if untreated, could develop into cervical cancer, but also to detect HPV disease (the human response to HPV infection) and to indicate the need for further diagnostic procedures.